CTOs on the Move

Harvard Vanguard Medical Associates

www.harvardvanguard.org

 
At Harvard Vanguard Medical Associates, our staff is our most important resource. That's why we offer challenging work, career advancement, competitive salaries and a benefits program that is among the best in the marketplace. The following summary is
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

AdCare Health Systems

Founded in 1991, AdCare Health Systems, Inc. (NYSE MKT: ADK) is a leading provider of senior living and health care facility management, dedicated to providing the highest quality of healthcare services to the elderly. AdCare operates 46 facilities in Alabama, Arkansas, Georgia, Ohio, Oklahoma, North Carolina, Missouri and South Carolina, with approximately 4,700 beds in service. The facilities comprise 43 skilled nursing centers, three assisted living residences and one senior independent living facility. AdCare owns 24 of the skilled nursing centers and two of the assisted living facilities, with the others operated under long-term lease, consolidated variable interest entity, or management contract.

National Rural Health Association

National Rural Health Association is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ATS Health Services

ATS Health Services is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ready Clinic

Ready Clinic is a privately owned family practice staffed with Nurse Practitioners with locations in Ringgold, Flintstone & Lafayette GA. We provide high-quality care with the understanding that each and everyone deserves to be treated with the highest...

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.